EAM
Eventide Asset Management’s Keros Therapeutics KROS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-380,000
| Closed | -$6.02M | – | 242 |
|
|
2024
Q4 | $6.02M | Hold |
380,000
| – | – | 0.11% | 151 |
|
|
2024
Q3 | $22.1M | Sell |
380,000
-119,208
| -24% | -$6.92M | 0.38% | 83 |
|
|
2024
Q2 | $22.8M | Sell |
499,208
-180,792
| -27% | -$8.26M | 0.39% | 82 |
|
|
2024
Q1 | $45M | Buy |
680,000
+100,000
| +17% | +$6.62M | 0.71% | 52 |
|
|
2023
Q4 | $23.1M | Hold |
580,000
| – | – | 0.38% | 77 |
|
|
2023
Q3 | $18.5M | Hold |
580,000
| – | – | 0.33% | 89 |
|
|
2023
Q2 | $23.3M | Buy |
580,000
+280,000
| +93% | +$11.3M | 0.39% | 78 |
|
|
2023
Q1 | $12.8M | Buy |
+300,000
| New | +$12.8M | 0.24% | 112 |
|
|
2021
Q3 | – | Sell |
-427,414
| Closed | -$18.2M | – | 155 |
|
|
2021
Q2 | $18.2M | Hold |
427,414
| – | – | 0.24% | 99 |
|
|
2021
Q1 | $26.3M | Buy |
427,414
+81,414
| +24% | +$5.01M | 0.39% | 81 |
|
|
2020
Q4 | $24.4M | Buy |
+346,000
| New | +$24.4M | 0.37% | 79 |
|